Seely Lynn 4

What Happened
Seely Lynn, President & CEO and director of Lyell Immunopharma (LYEL), received awards/derivative grants and had a small automatic sale to cover taxes. On Feb 9, 2026 Lynn was issued 20,000 shares (performance-based RSUs) at $0.00 per share after performance criteria were certified. On Feb 10, 2026 Lynn was granted a 155,000-share derivative award (reported at $0.00). Also on Feb 10, 2026 Lynn sold 438 shares in an open-market/private sale at $23.12 per share, generating proceeds of $10,127.

Key Details

• Transaction dates: Feb 9, 2026 (20,000 RSUs issued); Feb 10, 2026 (155,000 derivative grant; 438-share sale). Filing date: Feb 11, 2026 (covers Feb 9–10 transactions).
• Sale price/value: 438 shares @ $23.12 = $10,127 (disposed).
• Award values: 20,000 and 155,000 shares reported at $0.00 (awards/derivative grants).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: 20,000 performance-based RSUs were issued upon certification of performance criteria (granted Feb 9, 2024; issued Feb 9, 2026).
  • F2: The 438 shares were automatically sold to cover tax withholding from the settlement of vested RSUs.
  • F3: The 155,000-share derivative award is subject to a vesting schedule: 12.5% vests six months after Feb 9, 2026, then 1/48th monthly thereafter until fully vested (typical multi-year vesting).
• Filing timeliness: Filed Feb 11, 2026 for transactions on Feb 9–10; appears to be within the normal Form 4 reporting window.

Context
The sizable entries are awards/derivative grants (not open-market purchases) and are subject to vesting — they do not represent immediately marketable shares. The small sale was an automatic, routine tax-withholding sale tied to RSU settlement, not necessarily a discretionary sell signal.